AptarGroup, Inc. (ATR) 股票分析

公司概述

AptarGroup, Inc. operates as a specialized manufacturer and designer of drug delivery systems, consumer product dispensing mechanisms, and advanced material science solutions serving the pharmaceutical, fragrance, skincare, cosmetics, personal care, home care, and food and beverage sectors. The company functions within the Healthcare sector, specifically targeting the Medical Instruments & Supplies industry, where it provides critical infrastructure for product application across various therapeutic and consumer categories. AptarGroup, Inc. commands a substantial market position with a total market capitalization of $8.46 billion, generating annual recurring revenue of $3.78 billion while employing approximately 14,000 individuals globally. These financial scales indicate that the entity is a significant player in its niche, possessing the resources to maintain extensive supply chains and R&D capabilities required for serving diverse global markets ranging from prescription pharmaceuticals to over-the-counter consumer goods.

财务健康

The company reported a trailing twelve-month revenue of $3.78 billion and net income of $392.79 million, while EBITDA stood at $803.58 million, revealing a cost structure where non-operating expenses, interest, and taxes consume a significant portion of earnings before interest and taxes. Free cash flow for the period was $205.90 million, which reflects the cash generated after capital expenditures and indicates a baseline level of financial flexibility available for debt servicing, capital investments, or shareholder returns. The gross margin stands at 37.2%, suggesting a moderate pricing power relative to the cost of goods sold in a manufacturing-intensive environment, while the operating margin of 11.3% and profit margin of 10.4% demonstrate that operational overhead and tax obligations reduce pre-tax earnings further to arrive at the bottom line. On the balance sheet, the company holds $409.53 million in cash against $1.55 billion in total debt, resulting in a debt-to-equity ratio of 57.10, which characterizes a leveraged capital structure where debt obligations exceed equity capitalization. Despite the leverage, the current ratio of 1.62 suggests adequate short-term liquidity, as current assets are more than double current liabilities, providing a buffer against immediate operational obligations. Return on equity is measured at 15.1% and return on assets at 6.7%, indicating that management is effectively utilizing shareholders' equity to generate returns, although the lower ROA relative to ROE highlights the impact of the company's high debt load on overall asset efficiency.

估值评估

Valuation metrics show a trailing P/E ratio of 22.31 compared to a forward P/E of 20.64, implying that the market anticipates a normalization or slight contraction in earnings growth in the coming year to justify the lower multiple relative to current profitability. The price-to-book ratio is recorded at 3.16, indicating that the market values the company at more than three times its book value, which typically suggests a premium assigned to intangible assets, brand equity, or growth prospects not fully captured on the balance sheet. Alternative valuation indicators include a price-to-sales ratio of 2.24 and an EV/EBITDA of 12.00, which provide context by comparing enterprise value to cash generation and sales, offering a broader perspective on valuation that accounts for debt and cash positions. Price action analysis reveals a 52-week high of $164.28 and a 52-week low of $103.23, meaning the stock trades within a compressed range that reflects recent market volatility and sentiment shifts over the last year. The beta value of 0.49 indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the market index in either direction, which offers a defensive characteristic for risk-averse portfolios.

Growth & Income

Growth dynamics display a revenue growth rate of 13.5% year-over-year contrasted against an earnings growth rate of -23.5%, indicating that earnings are contracting significantly faster than top-line sales, likely due to margin compression or one-time costs affecting the bottom line. As a dividend payer, the company offers a yield of 1.4% with a payout ratio of 31.1%, suggesting a sustainable dividend policy given that the payout represents a small fraction of net income, leaving ample room for earnings volatility without jeopardizing shareholder distributions. The disparity between robust revenue expansion and declining earnings growth highlights a temporary disconnect where sales volume increases are not yet translating into proportional profit growth. Overall, the company presents a profile of strong sales momentum tempered by earnings contraction, supported by a stable but leveraged balance sheet and a consistent dividend commitment that provides income alongside exposure to the healthcare products sector.